Pain Therapeutics announces initiation of a phase II study in Alzheimer’s disease
Pain Therapeutics announced initiation of a Phase II study to evaluate PTI-125 as a potential first line treatment in patients with Alzheimer’s disease. This clinical study is supported by a research grant award from the National Institute on Aging. December 06, 2018